BioNTech Falls Short In Jittery IPO Market
Investors also readjust to firm's unproven pipeline
After ADC Therapeutics postponed its launch last week, BioNTech braves the markets but finds them less receptive than hoped.
After ADC Therapeutics postponed its launch last week, BioNTech braves the markets but finds them less receptive than hoped.